Immunohistochemical expression of phospho-Akt in uveal melanoma
Immunohistochemical expression of phospho-Akt in uveal melanoma
复制标题
DOI：
10.1097/00008390-200508000-00003
复制
发表时间：
2005-08-01
影响因子：
2.2
通讯作者：
Burnier, MN
中科院分区：
文献类型：
--
作者：
Saraiva, VS;Caissie, AL;Burnier, MN
本研究的目的是探讨葡萄膜黑色素瘤中磷酸化Akt的免疫组织化学表达及其与临床病理特征的关系。34例脉络膜黑色素瘤患者的34只眼被摘除。根据所接受的治疗分为两组：(1)直接眼球摘除组(n=18)；(2)外照射或近距离放射治疗组(n=16)。获得临床病理资料。最短随访时间为72个月。用抗磷酸化Akt(Ser473)兔抗体进行磷酸化Akt的免疫组织化学染色。在每一组患者中，分别研究磷酸化Akt与临床病理参数的关系。磷酸化Akt免疫染色两组均为胞浆阳性。初次摘除组有10个肿瘤呈磷酸化Akt阳性(55.5%)。磷酸化Akt阳性肿瘤的患者年龄较大(平均70.8岁对59岁，P=0.01)，并且磷酸化Akt免疫反应与更高的转移疾病风险显著相关(Kaplan-Meier分析，P=0.02)。放疗联合摘除组有9个肿瘤呈磷酸化Akt阳性(56.2%)。磷酸化Akt表达缺失与男性相关(P=0.02)。本研究可得出以下结论：(1)55.5%的葡萄膜黑色素瘤和56.2%的葡萄膜黑色素瘤放射联合摘除术后均有磷酸化Akt免疫表达；(2)磷酸化Akt免疫表达与包括预后在内的临床病理特征之间的关系值得进一步研究。
The aim of this study was to evaluate the immunohistochemical expression of phospho-Akt and its possible association with clinicopathological features in uveal melanoma. Thirty-four enucleated eyes from 34 patients with choroidal melanoma were included in the study. Patients were divided into two groups based on the treatment received: (1) primary enucleation (n=18); (2) radiotherapy, either external beam or brachytherapy, and enucleation (n=16). Clinicopathological data were obtained. The minimum follow-up time was 72 months. Immunohistochemistry for phospho-Akt was performed using an anti-phospho-Akt (Ser 473) rabbit antibody. The association of phospho-Akt with clinicopathological parameters was investigated in each patient group separately. Phospho-Akt immunostaining was cytoplasmic in both groups. In the primary enucleation group, 10 tumours were phospho-Akt positive (55.5%). Patients with phospho-Akt-positive tumours were older (average 70.8 years versus 59 years, P=0.01) and phospho-Akt immunoreactivity was significantly associated with a higher risk of metastatic disease (Kaplan-Meier analysis, P=0.02). In the radiotherapy and enucleation group, nine tumours were phospho-Akt positive (56.2%). The absence of phospho-Akt expression was correlated with male gender (P=0.02). The following conclusions can be drawn from this study: (1) phospho-Akt immunoexpression was detected in 55.5% of uveal melanomas treated with primary enucleation and in 56.2% of uveal melanomas treated with radiotherapy and enucleation; (2) the association of phospho-Akt immunoexpression with clinicopathological features including prognosis, merits further study.